CO6630125A2 - Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis - Google Patents

Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis

Info

Publication number
CO6630125A2
CO6630125A2 CO12170798A CO12170798A CO6630125A2 CO 6630125 A2 CO6630125 A2 CO 6630125A2 CO 12170798 A CO12170798 A CO 12170798A CO 12170798 A CO12170798 A CO 12170798A CO 6630125 A2 CO6630125 A2 CO 6630125A2
Authority
CO
Colombia
Prior art keywords
gestagen
endometriosis
treatment
ovarian
aromatase
Prior art date
Application number
CO12170798A
Other languages
English (en)
Inventor
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Harri Jukarainen
Henriikka Korolainen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6630125(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CO6630125A2 publication Critical patent/CO6630125A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

El contenido de la presente invención para el tratamiento de endometriosis consiste en proporcionar una forma farmacéutica parenteral (sistema de administración) para la liberación controlada de un inhibidor de aromatasa (Al) con una tasa de liberación diaria, que no induce una estimulación de los ovarios por re acoplamiento negativo del eje hipófisis-ovario (que provocaría una secreción de gonadotropinas y estimulación del crecimiento folicular ovárico), y de un gestágeno con una tasa de liberación diaria inferior a la dosis inhibidora de la ovulación, que pone a disposición una acción anticonceptiva sobre la base de acciones locales (por ejemplo, reducción y espesamiento de la mucosa cervical, para impedir que suban los espermatozoides, efectos sobre el endometrio y sobre la motilidad de las trompas, a fin de evitar la implantación y el transporte de óvulos).
CO12170798A 2010-03-31 2012-09-28 Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis CO6630125A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose

Publications (1)

Publication Number Publication Date
CO6630125A2 true CO6630125A2 (es) 2013-03-01

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12170798A CO6630125A2 (es) 2010-03-31 2012-09-28 Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (es)
EP (1) EP2552404B1 (es)
JP (2) JP6012048B2 (es)
KR (1) KR20130010047A (es)
CN (1) CN103002873B (es)
AR (1) AR080861A1 (es)
AU (1) AU2011234587B2 (es)
BR (1) BR112012024739A2 (es)
CA (1) CA2794790A1 (es)
CL (1) CL2012002722A1 (es)
CO (1) CO6630125A2 (es)
CR (1) CR20120493A (es)
CU (1) CU20120145A7 (es)
CY (1) CY1116187T1 (es)
DE (1) DE102010003494A1 (es)
DK (1) DK2552404T3 (es)
DO (1) DOP2012000255A (es)
EA (1) EA025582B1 (es)
EC (1) ECSP12012176A (es)
ES (1) ES2533101T3 (es)
GT (1) GT201200267A (es)
HK (1) HK1179531A1 (es)
HR (1) HRP20150294T1 (es)
IL (1) IL222056A (es)
MA (1) MA34099B1 (es)
ME (1) ME02159B (es)
MX (1) MX2012011329A (es)
MY (1) MY160353A (es)
NZ (1) NZ602698A (es)
PE (1) PE20130524A1 (es)
PL (1) PL2552404T3 (es)
PT (1) PT2552404E (es)
RS (1) RS53876B1 (es)
SG (1) SG184111A1 (es)
SI (1) SI2552404T1 (es)
TN (1) TN2012000468A1 (es)
TW (2) TWI576107B (es)
UA (1) UA109655C2 (es)
UY (1) UY33303A (es)
WO (1) WO2011120925A1 (es)
ZA (1) ZA201206869B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112017025097B1 (pt) * 2015-05-27 2021-05-11 Quest Diagnostics Investments Llc método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6936801B2 (ja) * 2015-12-21 2021-09-22 バイエル・オーイュー 薬剤送達装置の製造方法およびその方法に従って製造された薬剤送達装置
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A (fi) * 2000-03-13 2001-09-14 Leiras Oy Implantaattien asettamiseen tarkoitettu laite
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
WO2011120925A1 (de) 2011-10-06
BR112012024739A2 (pt) 2016-06-07
TW201632184A (zh) 2016-09-16
JP6012048B2 (ja) 2016-10-25
MY160353A (en) 2017-02-28
EA201201358A1 (ru) 2013-04-30
PL2552404T3 (pl) 2015-05-29
TN2012000468A1 (en) 2014-01-30
TW201201799A (en) 2012-01-16
MA34099B1 (fr) 2013-03-05
ZA201206869B (en) 2016-01-27
CU20120145A7 (es) 2013-05-31
GT201200267A (es) 2014-06-04
IL222056A (en) 2016-03-31
JP2016164200A (ja) 2016-09-08
PT2552404E (pt) 2015-03-30
CL2012002722A1 (es) 2013-01-18
PE20130524A1 (es) 2013-04-26
DE102010003494A1 (de) 2011-10-06
UA109655C2 (uk) 2015-09-25
SI2552404T1 (sl) 2015-04-30
HRP20150294T1 (hr) 2015-06-19
NZ602698A (en) 2014-08-29
CN103002873B (zh) 2015-02-18
ECSP12012176A (es) 2012-10-30
SG184111A1 (en) 2012-10-30
ES2533101T3 (es) 2015-04-07
CR20120493A (es) 2012-11-22
DK2552404T3 (en) 2015-03-30
ME02159B (me) 2015-10-20
AU2011234587A1 (en) 2012-10-25
EA025582B1 (ru) 2017-01-30
US20130131027A1 (en) 2013-05-23
JP2013523683A (ja) 2013-06-17
RS53876B1 (en) 2015-08-31
MX2012011329A (es) 2012-11-30
US20150359802A1 (en) 2015-12-17
CA2794790A1 (en) 2011-10-06
AU2011234587B2 (en) 2015-07-09
EP2552404B1 (de) 2015-01-21
TWI576107B (zh) 2017-04-01
CY1116187T1 (el) 2017-02-08
EP2552404A1 (de) 2013-02-06
DOP2012000255A (es) 2013-04-30
HK1179531A1 (en) 2013-10-04
KR20130010047A (ko) 2013-01-24
CN103002873A (zh) 2013-03-27
AR080861A1 (es) 2012-05-16
UY33303A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
CO6630125A2 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis
PE20142239A1 (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos
AU2018200234B2 (en) Intrauterine contraceptive device
CL2016003295A1 (es) Dosificación intermitente de un inhibidor de mdm2.
BR112019006227A2 (pt) métodos de tratamento de leiomioma uterino e endometriose
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
CY1114260T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγο, μεθοδοι για την παραγωγη αυτου και χρηση αυτου για την αγωγη παθησεων
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
CU20190096A7 (es) Compuestos derivados de 3-metil-3-hidroxi-4-[(n,n-dimetil)amino]-9-[2-(benciloxi)bencil]-1-oxa-9-azaspiro[5,5]undecano substituidos como inhibidores de la función mitocondrial y composiciones farmacéuticas que los contienen
CR20150282A (es) Método para sincronización del tiempo de inseminación en cerdas jóvenes
CL2017002920A1 (es) Régimen modulador selectivo de los receptores de progesterona (sprm).
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
TH133904A (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
UA100790U (uk) Спосіб лікування симптомної лейоміоми матки
Elovitz The rationale for use of progesterone in the prevention of preterm birth?
TH115297A (th) ระบบที่อยู่ภายในมดลูก (Intrauterine System) สำหรับการใช้ในการบำบัดทางการแพทย์
TH133904B (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
UY35526A (es) Derivados de espiroindolina y composiciones farma céuticas de los mismos
UA99532U (uk) Спосіб підвищення запліднюваності кобил проведенням санації внутрішніх статевих органів
Nayot Headache: 3 case reports
Gastal et al. Reuse of vaginal devices after autoclaving on rates parameters in sheep.
RU2009118754A (ru) Способ профилактики эндометрита у коров
UA100789U (uk) Спосіб лікування пацієнток з аномальними матковими кровотечами на тлі антикоагуляційної терапії
EA201200879A1 (ru) Устройство для введения внутриматочного средства контрацепции